拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析*

doi:10.3969/j.issn.1672-5069.2020.04.011

摘要/Abstract

摘要： 目的分析应用拉米夫定和替比夫定阻断乙型肝炎病毒(HBV)宫内感染的疗效和风险。方法 2014年6月~2018年6月在我院肝病科和妇产科就诊的慢性HBV携带孕妇120例,在孕28周时,其中40例接受拉米夫定,40例接受替比夫定治疗,分娩后立即停止抗病毒治疗,另20例在孕期未接受抗病毒治疗。新生儿出生后按计划接受标准的乙肝疫苗和乙型肝炎免疫球蛋白注射,随访1年。采用实时荧光定量 PCR法检测血清HBV DNA,采用电化学发光法检测血清HBsAg和HBsAb。结果入组时,三组孕妇血清HBV DNA水平无统计学差异(P>0.05);分娩时,接受拉米夫定和替比夫定治疗的孕妇血清HBV DNA转阴,显著低于对照组【(7.6±1.5)lg copies/ml,P<0.05】,在分娩后3个月,两组抗病毒治疗的孕妇血清HBV DNA水平再次回到治疗前水平,与对照组比,无显著性差异(P<0.05);在出生时,40例拉米夫定治疗、40例替比夫定治疗和21例未接受抗病毒治疗孕妇所生的新生儿血清HBsAg阳性率分别为5.0%、5.0%和9.5%(P>0.05),在出生后1年,他们血清HBsAg阳性率分别为7.5%、5.0%和14.3%,而血清抗HBs阳性率则分别为92.5%、95.0%和85.7%,也无显著性差异(P>0.05);在接受抗病毒药物治疗期间,拉米夫定组孕妇发生皮疹、一过性ALT升高和肌酸激酶升高分别为5.0%、2.5%和2.5%,与替比夫定组的2.5%、7.5%和5.0%比,差异无统计学意义(P>0.05)。结论在孕后期应用拉米夫定或替比夫定抗病毒治疗均可有效降低HBV携带孕妇血清HBV DNA水平,对阻断新生儿HBV母婴传播是否有必要,还需要进一步扩大样本量和长期随访观察。

关键词: 乙型肝炎病毒携带者, 拉米夫定, 替比夫定, 宫内感染, 母婴传播, 孕妇

Abstract: Objective The aim of this study was to analyze the efficacy and risks of lamivudine and telbivudine in blocking mother-to-infant intrauterine infection of hepatitis B virus (HBV). Methods 120 pregnant women with chronic hepatitis B viral carrier were enrolled in our hospital between June 2014 and June 2018, and at gestation 28 week, 40 pregnant women received lamivudine, 40 received telbivudine for antiviral therapy, and another 20 did not receive any antiviral agents. The antiviral regimen discontinued immediately after giving birth. All women and their children were followed-up for 12 months. Serum HBV DNA, HBsAg and HBsAb were assayed. Results At presentation, serum HBV DNA loads in the three groups were not significantly different (P>0.05); at delivery, serum HBV DNA loss were 100.0% in both groups receiving anti-viral therapy, hence their serum viral loads were significantly lower than that in the women without antiviral therapy 【(7.6±1.5)lg copies/ml, P<0.05】, and three months after delivery, serum HBV DNA in the two antiviral groups returned back to high levels before enrollment, without significantly differences to that in the control (P<0.05); at delivery, serum HBsAg prevalence in 40 newborns in lamivudine-treated, 40 in telbivudine-treated, and 21 in non-antiviral therapy group were 5.0%, 5.0% and 9.5%(P>0.05), and atone year old, their serumHBsAg prevalence were 7.5%, 5.0% and 14.3%, with serum anti-HBs positive rates of 92.5%, 95.0% and 85.7%, respectively(P>0.05); during antiviral therapy, the incidence of rash, transient serum ALT elevation and creatinene kinase elevation in women with lamivudine treatment were 5.0%, 2.5% and 2.5%, not much different as compared to 2.5%, 7.5% and 5.0%, in telbivudine-treated women (P>0.05). Conclusion Both lamivudine and telbivudine could effectively reduce serum HBV DNA loads in pregnant women with hepatitis B infection, which might help block HBV intrauterine infection from mother to infants, and the medication is relatively safe as no severe untoward effects is found during the antiviral therapy.

Key words: Hepatitis B viral carriers, Lamivudine, Tibivudine, Intrauterine infection, Mother-to-child transmission, Pregnancy

赵蕾, 李小丹, 刘淼. 拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 496-499.

Zhao Lei, Li Xiaodan, Liu Miao. Efficacy and risk analysis of lamivudine and telbivudine in blockingmother-to-child intrauterine infection of hepatitis B virus[J]. Journal of Practical Hepatology, 2020, 23(4): 496-499.

参考文献

[1]Lu F, Wang J, Chen X, et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med, 2017, 11(4): 502-508.
[2]Shu J, Zhao JN, Han FG, et al. Chronic hepatitis B: correlation of abnormal features on t2-weighted imaging and dynamic contrast-enhanced imaging with hepatic histopathology. Radiol Med, 2017, 122(11): 807-813.
[3]包依夏姆·阿巴拜克力, 努力比亚·阿不杜克尤木, 张跃新. 乙肝疫苗联合HBIG接种阻断HBsAg/HBeAg双阳性孕妇HBV母婴传播的效果研究. 实用肝脏病杂志, 2017, 20(2): 248-249.
[4]Bai X, Yang H, Wan L, et al. Involvement of viperin in prevention of intrauterine transmission of hepatitis B virus. APMIS, 2017, 125(2): 170-175.
[5]Shih YF, Liu CJ. Mother-to-infant transmission of hepatitis b virus: challenges and perspectives. Hepatol Int, 2017, 11(6): 481-484.
[6]刘书宏, 梁尘格, 向毅, 等. 不同核苷(酸)类药物治疗乙型肝炎相关性肝癌患者成本效益分析. 实用肝脏病杂志, 2018, 21(2): 293-294.
[7]中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[8]康富标, 孙殿兴, 李东, 等. 干扰素-α 2b治疗非母婴传播HBeAg阳性慢性乙型肝炎患者疗效分析. 实用肝脏病杂志, 2016, 19(4): 471-473.
[9]Su S, Fairley CK, Sasadeusz J, et al. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan Province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome. J Med Virol, 2018, 90(3): 518-525.
[10]Calisti G, Muhindo R, Boum YN, et al. Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy. Trans R Soc Trop Med Hyg, 2015, 109(11): 723-729.
[11]Liu J, Feng Y, Wang J, et al. An "immune barrier" is formed in the placenta by hepatitis B immunoglobulin to protect the fetus from hepatitis b virus infection from the mother. Hum Vaccin Immunother, 2015, 11(8): 2068-2076.
[12]赵媛, 曹耀章, 房荣, 等. 替比夫定对HBV高载量孕妇母婴传播阻断的疗效及安全性:一项随机对照研究. 实用肝脏病杂志, 2017, 20(2): 157-160.
[13]Peng S, Wan Z, Liu T, et al. Incidence and risk factors of intrauterine transmission among pregnant women with chronic hepatitis b virus infection. J Clin Gastroenterol, 2019, 53(1): 51-57.
[14]Floridia M, Masuelli G, Tamburrini E, et al. HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy. HIV Clin Trials, 2017, 18(2): 54-59.
[15]Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the single randomized clinical trial. J Acquir Immune Defic Syndr, 2015, 70(5): 515-519.
[16]Cerva C, Colagrossi L, Maffongelli G, et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-hbc-positive or hbv-negative recipients with an anti-hbc-positive donor. Clin Microbiol Infect, 2016, 22(11): 941-946.
[17]张先华. 替比夫定阻断血清HBV高载量孕妇母婴传播的疗效和安全性观察. 实用肝脏病杂志, 2015, 18(4): 411-412.
[18]Hu Y, Xu C, Xu B, et al. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study. J Viral Hepat, 2018, 25(4): 429-437.
[19]Chen ZX, Gu GF, Bian ZL, et al. Clinical course and perinatal transmission of chronic hepatitis b during pregnancy: a real-world prospective cohort study. J Infect, 2017, 75(2): 146-154.
[20]Han GR, Jiang HX, Wang CM, et al. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. J Viral Hepat, 2017, 24(6): 514-521.
[21]Yan Z, Qiao B, Zhang H, et al. Effectiveness of telbivudine antiviral treatment in patients with hepatitis b virus-associated glomerulonephritis: a 104-week pilot study. Medicine (Baltimore), 2018, 97(31): e11716.

拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析^*

Efficacy and risk analysis of lamivudine and telbivudine in blockingmother-to-child intrauterine infection of hepatitis B virus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	方利娟,吴雄飞. 恩替卡韦治疗乙型肝炎病毒携带者合并肺结核患者临床疗效分析[J]. 实用肝脏病杂志, 2020, 23(3): 340-343.
[2]	范凌, 杨军, 纪风兵, 周琴. 妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 179-182.
[3]	丁俊琪, 张偲, 张彬. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎部分应答患者序贯替比夫定治疗疗效观察^*[J]. 实用肝脏病杂志, 2020, 23(1): 26-29.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.
[8]	丁洋, 窦晓光. 如何实现乙型肝炎病毒母婴“零”传播?[J]. 实用肝脏病杂志, 2019, 22(1): 4-5.
[9]	王琦, 谢雯. 孕妇乙型肝炎病毒感染筛查与管理^*[J]. 实用肝脏病杂志, 2019, 22(1): 9-12.
[10]	朱娅鸽, 雷春梅, 郭丹丹, 陈天艳. 慢性乙型肝炎病毒感染孕妇及其婴幼儿随访管理研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 45-48.
[11]	谭静, 叶晓林, 王慧. 妊娠中晚期应用替比夫定阻断HBsAg阳性孕妇HBV母婴传播效果及对婴儿接种乙肝疫苗应答的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 49-52.
[12]	徐静, 陶琳琳, 叶娇娇, 张蕊, 王加加, 袁莉莉, 赵俊奖. 替比夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化患者疗效及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 89-92.
[13]	徐国荣, 柴丽莉. 乙肝疫苗联合乙型肝炎免疫球蛋白接种阻断血清HBsAg阳性母亲HBV母婴传播效果分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 851-854.
[14]	明全, 王淑平, 黎春宇, 杨艳艳. 拉米夫定与阿德福韦酯联合治疗失代偿期乙型肝炎肝硬化患者临床疗效研究[J]. 实用肝脏病杂志, 2018, 21(4): 627-628.
[15]	翁叶蕊, 符爱贞. HBV感染对孕妇产后母乳喂养的影响及护理策略[J]. 实用肝脏病杂志, 2018, 21(3): 457-458.